May 15, 2026 | FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval

Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal

FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavneos, and Lilly's orforglipron PDUFA lands Monday. Www.thepharacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Viridian Therapeutics, Lumvoa, veligrotug, thyroid eye disease, Amgen, Tepezza, Merck KGaA, Bio-Techne, Biogen, Apellis, Syfovre, Eli Lilly, orforglipron, Moderna, Ionis, Tryngolza, Ardelyx, Xphozah, Sanofi, Tavneos, avacopan, CHMP, Keytruda, Padcev, Replimune, Lycia, Dr. Reddy's, Gilead, AbbVie, M&A, GLP-1, Lilly, Merck, J&J

Jun 25, 2026 | Ionis Tryngolza FDA Label Expansion Hits Commercial Inflection

FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTUS limits Bayer Roundup state-level claims; Gilead-Pfizer ADC divergence deepens. pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Ionis, Tryngolza, olezarsen, hypertriglyceridemia, pancreatitis, FDA approval, Merck KGaA, Bio-Techne, Bayer, Roundup, SCOTUS, Gilead, Trodelvy, Pfizer, Seagen, ADC, AbbVie, Apogee, Ollin, Vabysmo, Novartis, Antares, pelacarsen, RQ Bio, Oblenio Bio, Remix, Passage Bio, Eli Lilly, orforglipron, Recordati, Lilly, Roche, Merck

Jun 24, 2026 | FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal

Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets, and three ADC stories in two days force a class-level reckoning. pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Trodelvy, sacituzumab govitecan, Gilead, TNBC, triple-negative breast cancer, FDA approval, Eli Lilly, Abbisko Therapeutics, Novartis, Antares Therapeutics, ADC, antibody-drug conjugate, Pfizer, Ibrance, Ionis, triglycerides, Ollin, Vabysmo, ADC Therapeutics, Zynlonta, HHS, pelacarsen, BioNTech, Lilly, Roche

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification

Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung cancer, NSCLC, Incyte, Opzelura, Jakafi, ruxolitinib, CMS, Medicare Part D, Sangamo Therapeutics, zinc-finger nuclease, gene editing, Eli Lilly, Astellas, Moderna, mFlusiva, flu vaccine, Regenxbio, UniQure, gene therapy, Makary, Genentech, Novartis, Xolair, Braftovi, encorafenib, 340B, Sanofi, Houman Ashrafian, Bionyra, Osanni Bio, Lilly, AstraZeneca, Merck

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China.   Visit www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen, CAR-T, Claudin 18.2, solid tumor, gastric cancer, Merck, Prometheus Biosciences, IBD, Keytruda, HHS, RFK Jr, clinical trial reform, Moderna, mFlusiva, Alnylam, Pfizer, Kardigan, MacroGenics, TZIELD, Bionyra, cAMPfield, WuXi Biologics, Novartis, pelacarsen, UniQure, AMT-130, Novo Nordisk, ransomware, BMS